Search Results - "Mensa, F.J."

Safety of ABT-493 and ABT-530 Co-Administered in Patients with HCV Genotype 1–6 Infection: Results from the Surveyor-I and Surveyor-II Studies by Kwo, P, Poordad, F, Porcalla, A, Gane, E, Lalezari, J, Wyles, D, Liu, R, Kort, J, Mensa, F.J

Get full text

1212 PHARMACOKINETIC MODELLING OF THE RELATIONSHIP BETWEEN SUSTAINED VIROLOGICAL RESPONSE AND PLASMA CONCENTRATIONS OF FALDAPREVIR OR BI-207127 IN HCV GT1-INFECTED PATIENTS IN SOUND-C2 by Olson, S, Baron, K, Riggs, M, Böcher, W.O, Mensa, F.J

Get full text

High SVR Rates with the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection by Poordad, F, Felizarta, F, Wang, S, Asatryan, A, Hassanein, T, Aguilar, H, Lalezari, J, Overcash, J.S, Ng, T.I, Lovell, S.S, Lin, C.-W, Kort, J, Mensa, F.J

Get full text

100% SVR4 with ABT-493 and ABT-530 with or without Ribavirin in Treatment-Naïve HCV Genotype 3-Infected Patients with Cirrhosis by Kwo, P.Y, Wyles, D.L, Wang, S, Poordad, F, Gane, E, Maliakkal, B, Shiffman, M.L, Ng, T.I, Lin, C.-W, Liu, R, Kort, J, Mensa, F.J

Get full text

High Svr Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection by Muir, A.J, Strasser, S, Wang, S, Shafran, S, Bonacini, M, Kwo, P, Wyles, D, Gane, E, Lovell, S.S, Lin, C.-W, Ng, T.I, Kort, J, Mensa, F.J

Get full text

High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study by Poordad, F, Gordon, S.C, Asatryan, A, Felizarta, F, Reindollar, R.W, Landis, C, Fried, M.W, Bernstein, D.E, Ng, T.I, Lin, C.-W, Liu, R, Kort, J, Mensa, F.J

Get full text

1186 ITPA GENE VARIANTS PREDICT HEMOLYTIC RIBAVIRIN INDUCED ANAEMIA IN PATIENTS TREATED WITH THE INTERFERON-FREE REGIMEN OF FALDAPREVIR, BI 207127 AND RIBAVIRIN IN SOUND-C2 by Asselah, T, Zeuzem, S, Soriano, V, Bronowicki, J.-P, Lohse, A.W, Müllhaupt, B, Schuchmann, M, Bourliere, M, Buti, M, Roberts, S, Gane, E, Stern, J.O, Voss, F, Baum, P, Gallivan, J.-P, Böcher, W.O, Mensa, F.J

Get full text

1227 AN ANALYSIS OF RESPONSE RATES BY FIBROSIS STAGE IN PATIENTS TREATED WITH FALDAPREVIR, BI 207127 AND RIBAVIRIN IN THE SOUND-C2 STUDY by Zeuzem, S, Soriano, V, Asselah, T, Bronowicki, J.-P, Lohse, A.W, Müllhaupt, B, Schuchmann, M, Bourliere, M, Buti, M, Roberts, S, Gane, E, Stern, J.O, Voss, F, Baum, P, Gallivan, J.-P, Böcher, W.O, Mensa, F.J

Get full text

101 SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2 by Zeuzem, S, Soriano, V, Asselah, T, Bronowicki, J.-P, Lohse, A, Müllhaupt, B, Schuchmann, M, Bourliere, M, Buti, M, Roberts, S, Gane, E, Stern, J.O, Kukolj, G, Dai, L, Böcher, W.O, Mensa, F.J

Get full text

SAT-239 - Safety of ABT-493 and ABT-530 Co-Administered in Patients with HCV Genotype 1–6 Infection: Results from the Surveyor-I and Surveyor-II Studies by Kwo, P., Poordad, F., Porcalla, A., Gane, E., Lalezari, J., Wyles, D., Liu, R., Kort, J., Mensa, F.J.

Get full text

SAT-157 - High SVR Rates with the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection by Poordad, F., Felizarta, F., Wang, S., Asatryan, A., Hassanein, T., Aguilar, H., Lalezari, J., Overcash, J.S., Ng, T.I., Lovell, S.S., Lin, C.-W., Kort, J., Mensa, F.J.

Get full text

LB01 - 100% SVR4 with ABT-493 and ABT-530 with or without Ribavirin in Treatment-Naïve HCV Genotype 3-Infected Patients with Cirrhosis by Kwo, P.Y., Wyles, D.L., Wang, S., Poordad, F., Gane, E., Maliakkal, B., Shiffman, M.L., Ng, T.I., Lin, C.-W., Liu, R., Kort, J., Mensa, F.J.

Get full text

GS11 - High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study by Poordad, F., Gordon, S.C., Asatryan, A., Felizarta, F., Reindollar, R.W., Landis, C., Fried, M.W., Bernstein, D.E., Ng, T.I., Lin, C.-W., Liu, R., Kort, J., Mensa, F.J.

Get full text

PS098 - High Svr Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection by Muir, A.J., Strasser, S., Wang, S., Shafran, S., Bonacini, M., Kwo, P., Wyles, D., Gane, E., Lovell, S.S., Lin, C.-W., Ng, T.I., Kort, J., Mensa, F.J.

Get full text